The development of endoxifen for breast cancer

Matthew P. Goetz

The development of endoxifen for breast cancer

Medical Oncology

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	102-105
Number of pages	4
Journal	Clinical Advances in Hematology and Oncology
Volume	16
Issue number	2
State	Published - Feb 2018

ASJC Scopus subject areas

Hematology
Oncology

Cite this

@article{9391574d763b430e89dc165b1460c4fb,

title = "The development of endoxifen for breast cancer",

author = "Goetz, {Matthew P.}",

note = "Funding Information: Dr Goetz has a consulting or advisory role for Eli Lilly, Biotheranostics, Biovica, Myriad, and Genomic Health. He has received research funding from Eli Lilly and Pfizer.",

year = "2018",

month = feb,

language = "English (US)",

volume = "16",

pages = "102--105",

journal = "Clinical Advances in Hematology and Oncology",

issn = "1543-0790",

publisher = "Millennium Medical Publishing, Inc.",

number = "2",

}

TY - JOUR

T1 - The development of endoxifen for breast cancer

AU - Goetz, Matthew P.

N1 - Funding Information: Dr Goetz has a consulting or advisory role for Eli Lilly, Biotheranostics, Biovica, Myriad, and Genomic Health. He has received research funding from Eli Lilly and Pfizer.

PY - 2018/2

Y1 - 2018/2

UR - http://www.scopus.com/inward/record.url?scp=85042487169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042487169&partnerID=8YFLogxK

M3 - Comment/debate

C2 - 29741509

AN - SCOPUS:85042487169

SN - 1543-0790

VL - 16

SP - 102

EP - 105

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

IS - 2

ER -

The development of endoxifen for breast cancer

ASJC Scopus subject areas

Other files and links

Cite this